600420.SS
600420.SS
CNE000001JG2
SHANGHAI SHYNDEC PHARMACEUTICAL
Loading chart...

Company Profile

Shanghai Shyndec Pharmaceutical Co., Ltd. engages in the research and development, production, and sale of pharmaceutical products in China. The company provides nifedipine controlled release tablets, penicillin industrial potassium salt, touboke yuekui granules/capsules, sodium cefuroxime for injection, D-7ACA, fermented products, milnacipran hydrochloride tablets, compound licorice tablets, and cefoperazone dispersible tablets; and cefuroxime axetil tablets, cefuroxime sodium for injection, cefaclor extended-release capsules, cefixime granules, and cefdinir dispersible tablets. It also offers nifedipine controlled-release tablets, amlodipine besylate tablets, enalapril maleate tablet, pravastatin sodium tablets, olmesartan medoxomil hydrochlorothiazide tablets, olmesartan amlodipine tablets; milnaprom hydrochloride tablets, lofen codeine tablets, gastrodin injection, naloxone hydrochloride injection, piracetam injection; and apmis film, tacrolimus capsules, mannan peptide for injection, imatinib mesylate. In addition, the company provides methylprednisolone sodium succinate for injection, octreotide acetate injection, betamethasone sodium phosphate for injection, dexamethasone sodium phosphate injection; diclofenac sodium sustained release tablets; 6-aminopenicillinic acid, azithromycin, amoxicillin, potassium clavulanate microcrystalline cellulose, ceftriaxone sodium crude salt, 7-aminocephalosporanic acid, chorionic gonadotropin, urinary gonadotropin; and naphazoline hydrochloride nasal drops, Ambroxol Hydrochloride Oral Solution. Shanghai Shyndec Pharmaceutical Co., Ltd. was founded in 1996 and is based in Shanghai, China.

Related stocks

002755.SZ
002755.SZ • China
ASK PHARM
13.34 CNY
1.85B USD 1Y -32.7%
600572.SS
600572.SS • China
ZHEJIANG CONBA PHARMACEUTICAL C
4.41 CNY
1.68B USD 1Y +0.5%
600285.SS
600285.SS • China
HENAN LINGRUI PHARMACEUTICAL
19.66 CNY
1.67B USD 1Y -11.5%
600211.SS
600211.SS • China
TIBET RHODIOLA PHARMACEUTICAL H
36.78 CNY
1.77B USD 1Y -22.9%
605507.SS
605507.SS • China
GUOBANG PHARMA LTD
17.31 CNY
2.03B USD 1Y +7.4%
600812.SS
600812.SS • China
NORTH CHINA PHARMACEUTICAL CO
6.03 CNY
1.55B USD 1Y +1.5%
300026.SZ
300026.SZ • China
CHASE SUN PHARM.
3.32 CNY
1.49B USD 1Y -10.8%
603456.SS
603456.SS • China
ZHEJIANG JIUZHOU PHARMACEUTICAL
16.31 CNY
2.14B USD 1Y -20.9%

Key Metrics & Overview

Detailed metrics & financial data of the company

Company Profile
5 Metrics

🛡️ Risk & Structural Analysis

Multi-Factor Risk Model & Market Data

7/7 Very High
5Y Volatility
30.6% p.a.
Max Drawdown (5Y)
-45.6%
Sharpe Ratio (5Y)
-0.21
Beta Factor
0.10
Size Class
Large Cap
Notes & Warnings
Single Stock Risk: Investing in an individual stock carries full company and insolvency risk (no fund diversification).
Exemplary balance sheet strength: Very solid ratio of equity to debt.
Structurally High Volatility: Above-average fluctuations persist across 5 to 10 years (30.6% p.a.).
Historical Stress Test: Maximum peak-to-trough drawdown of -57.4% in the extended horizon.
ende